FIELD: chemistry.
SUBSTANCE: invention relates to use of compound of structural formula (I) or a pharmaceutically acceptable salt thereof for treating hepatitis C virus infection in a subject,
wherein R1 is selected from a group consisting of hydrogen and Q-C(=O)-; R2-R5 are hydrogen; wherein one of R6 or R7 is hydrogen, and other is (C1-C6)-alkylsuphinyl; wherein Q is R8 and R8 is selected from a group consisting of hydrogen and (C1-C12)-alkyl. Compound of formula (I) is also intended for preparing a drug for treating a subject infected with hepatitis C virus.
EFFECT: technical result is using alkylsulphinyl-substituted thiazolides to treat an infection caused by hepatitis C virus.
17 cl, 3 tbl
Title | Year | Author | Number |
---|---|---|---|
SUBSTITUTED 2-ACYL-2-AMINOTHIAZOLES | 2005 |
|
RU2371438C2 |
NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND USE THEREOF IN PHARMACEUTICAL PREPARATIONS | 2013 |
|
RU2701156C2 |
COMBINATION, INCLUDING A) PYRIMIDYLAMINOBENZAMIDE AND B) KINASE Thr315lle INHIBITOR | 2007 |
|
RU2481840C2 |
ISOSERINE DERIVATIVES APPLIED AS BLOOD COAGULATION FACTOR IXA INHIBITORS | 2007 |
|
RU2446157C2 |
ANTIVIRAL COMPOUNDS | 2009 |
|
RU2505540C2 |
ANTIVIRAL COMPOUNDS | 2009 |
|
RU2505539C2 |
SULPHONAMIDETHIAZOLE PYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS, SUITABLE FOR TREATING TYPE-2 DIABETES | 2005 |
|
RU2412192C2 |
CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM | 2018 |
|
RU2795146C2 |
QUINAZOLINE DERIVATIVES | 2004 |
|
RU2356896C2 |
NOVEL COMPOUNDS AS CATHEPSIN INHIBITORS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF, THEIR USING AND METHOD FOR THEIR PREPARING | 2002 |
|
RU2316546C2 |
Authors
Dates
2016-12-27—Published
2011-10-27—Filed